Epidemiologic and Clinical Analysis of Cervical Cancer Using Data from the Population-Based Osaka Cancer Registry

  • Asami Yagi
    1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Yutaka Ueda
    1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Mamoru Kakuda
    1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Yusuke Tanaka
    1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Sayaka Ikeda
    2Department of Gynecology, Tama-Hokubu Medical Center, Tokyo Metropolitan Health and Medical Treatment Corporation, Higashimurayama, Tokyo, Japan.
  • Shinya Matsuzaki
    1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Eiji Kobayashi
    1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Toshitaka Morishima
    3Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.
  • Isao Miyashiro
    3Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.
  • Keisuke Fukui
    4Research and Development Center, Osaka Medical College, Takatsuki, Osaka, Japan.
  • Yuri Ito
    4Research and Development Center, Osaka Medical College, Takatsuki, Osaka, Japan.
  • Tomio Nakayama
    5Center for Public Health Sciences, National Cancer Center, Chuo-ku, Tokyo, Japan.
  • Tadashi Kimura
    1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

Search this article

Description

<jats:title>Abstract</jats:title> <jats:sec> <jats:title/> <jats:p>Cervical cancer screening rate is extremely low and the governmental recommendation of HPV vaccine has been suspended for 5 years in Japan. Here, we utilized data from the Osaka Cancer Registry, collected between 1976 and 2012, to evaluate cervical cancer trends in Japan. Age-adjusted incidence, relative survival, and conditional survival rates were calculated using multiple imputation methods and period analyses in 25,826 cervical cancer cases. Association of survival rates and clinical factors, including patients' age, clinical stage, and treatment procedures, were also analyzed. A trend for significantly decreasing age-adjusted incidence of cervical cancer (per 100,000) began in 1976 but reversed after 2000, increasing significantly to date (annual percent change = 3.8, 95% confidence interval, 2.7–4.8; age-adjusted rate: 28.0 in 1976, 9.1 in 2000, 14.1 in 2012). The 10-year relative survival rate improved significantly after 2002, especially in cases of “localized” and “adjacent organs” disease; this was likely due to the introduction of concurrent chemotherapy and radiation. The conditional 5-year relative survival rate improved significantly yearly until the fourth survival year. In the surgery-based group, we observed no age-dependent differences in outcomes. Unexpectedly, however, prognosis for younger age groups was poorer in the radiation-based treatment group. These results indicate that although relative survival rates have recently increased, treatment for more advanced cases with distant metastasis requires further improvement. In addition, this study is the first to suggest that age might be an important predictor of radiotherapy resistance in cervical cancer.</jats:p> </jats:sec> <jats:sec> <jats:title/> <jats:p>Significance: A large-cohort analysis of cervical cancer cases reveals that age-adjusted incidence in Japan has increased since 2000 and that age may negatively correlate with resistance to radiotherapy.</jats:p> </jats:sec>

Journal

  • Cancer Research

    Cancer Research 79 (6), 1252-1259, 2019-03-15

    American Association for Cancer Research (AACR)

Citations (33)*help

See more

References(24)*help

See more

Related Projects

See more

Details 詳細情報について

Report a problem

Back to top